Abstract:BACKGROUND:Gliomas are the most common intracranial tumors and are classified as I-IV. Among them, glioblastoma multiforme (GBM) is the most common invasive glioma with a poor prognosis. New molecular biomarkers that can predict clinical outcomes in GBM patients must be identified, which will help comprehend their pathogenesis and supply personalized treatment. Our research revealed four powerful survival indicators in GBM by reanalyzing microarray data and genetic sequencing data in public databases. Moreover, it unraveled new potential therapeutic targets which could help improve the survival time and quality of life of GBM patients.MATERIALS AND METHODS:To identify prognostic signatures in GBMs, we analyzed the gene profiling data of GBM and standard brain samples from the Gene Expression Omnibus, including four datasets and RNA sequencing data from The Cancer Genome Atlas (TCGA) containing 152 glioblastoma tissues. We performed the differential analysis, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, weighted gene co-expression network analysis (WGCNA) and Cox regression analysis.RESULTS:After differential analysis in GSE12657, GSE15824, GSE42656 and GSE50161, overlapping differentially expressed genes were identified. We identified 110 up-regulated DEGs and 75 down-regulated DEGs in the GBM samples. Significantly enriched subclasses of the GO classification of these genes included mitotic sister chromatid separation, mitotic nuclear division and so on. In KEGG pathway analysis, the most abundant terms were ECM-receptor interaction and protein digestion and absorption. WGCNA analysis was performed on these 185 DEGs in 152 glioblastoma samples obtained from TCGA, and gene co-expression networks were constructed. We then performed a multivariate Cox analysis and established a Cox proportional hazards regression model using the top 20 genes significantly correlated with survival time. We identified a four-protein prognostic signature that could divide patients into high-risk and low-risk groups. Increased expression of SLC12A5, CCL2, IGFBP2, and PDPN was associated with increased risk scores. Finally, the K-M curves confirmed that these genes could be used as independent predictors of survival in patients with glioblastoma.CONCLUSION:Our analytical study identified a set of potential biomarkers that could predict survival and may contribute to successful treatment of GBM patients.

Microrna-1224-5p Is a Potential Prognostic and Therapeutic Biomarker in Glioblastoma: Integrating Bioinformatics and Clinical Analyses

Identify Signature Regulatory Network for Glioblastoma Prognosis by Integrative Mrna and Mirna Co-Expression Analysis.

Identification of Differentially Expressed Micrornas and the Potential of Microrna-455-3p As a Novel Prognostic Biomarker in Glioma

An Integrated Mrna and Microrna Expression Signature for Glioblastoma Multiforme Prognosis.

Gene and Microrna Signatures Are Associated with the Development and Survival of Glioblastoma Patients.

Mir-138-5p Suppresses Glioblastoma Cell Viability and Leads to Cell Cycle Arrest by Targeting Cyclin D3.

MicroRNA Signatures Predict Prognosis of Patients with Glioblastoma Multiforme Through the Cancer Genome Atlas.

Construction of Potential Glioblastoma Multiforme-Related Mirna-Mrna Regulatory Network

Identification of Potential Biomarkers of Platelet RNA in Glioblastoma by Bioinformatics Analysis.

Systematic analysis of the long noncoding RNA (lncRNA)-miRNA-mRNA competing endogenous RNA network to identify prognostic biomarkers and the potential regulatory axis in glioblastoma multiforme

Identification of novel prognostic targets in glioblastoma using bioinformatics analysis

Identification of serum exosomal miR-98-5p, miR-183-5p, miR-323-3p and miR-19b-3p as potential biomarkers for glioblastoma patients and investigation of their mechanisms

Bioinformatics Analysis and Experimental Validation for Exploring Key Molecular Markers for Glioblastoma

In Silico Analysis Identified Mirna-Based Therapeutic Agents Against Glioblastoma Multiforme

Identification of biomarkers and ceRNA network in glioblastoma through bioinformatic analysis and evaluation of potential prognostic values

Identification of an 8-Mirna Signature As a Potential Prognostic Biomarker for Glioma

Identification of potential biomarkers and candidate small molecule drugs in glioblastoma

Downregulation of Microrna-374A Predicts Poor Prognosis in Human Glioma

SV2B/miR-34a/miR-128 axis as prognostic biomarker in glioblastoma multiforme

Low Serum Level of Mir-485-3p Predicts Poor Survival in Patients with Glioblastoma.

Integrated Analysis to Evaluate the Prognostic Value of Signature Mrnas in Glioblastoma Multiforme